NCT06724848Recruiting
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
A Translational Study in Patients With COPD and Pre-COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on pre-COPD or PRISm, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants for 1-year period.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 850 (estimated)
- First submitted
- 8 May 2024
- Start date
- 5 Jun 2024
- Primary completion date
- 21 Oct 2027
- Lead sponsor
- AstraZeneca
- Diseases
- COPD
- NCT number
- NCT06724848
What you commit to
- Study type: Observational
- Planned participants: 850
- From 5 Jun 2024 to the primary completion date, 21 Oct 2027
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- COPD exacerbation, within 2 weeks prior to enrollment or during screening period.
- History of partial or total lung resection (single lobe or segmentectomy is acceptable). Surgical or endoscopic (eg, valves) lung volume reduction within the 6 months prior to enrollment. Expected need for lung volume reduction surgery during the study.
- Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrollment. Suspected malignancy or undefined neoplasms.
- Participants receipt marketed or investigational biologics biologics within 3 months or 5 half-lives prior to visit 1, whichever is longer.
Other illness
- The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation.
- Clinically important pulmonary disease.
- Unstable disorders.
- Terminal disease and/or organ failure or participants otherwise considered not appropriate for the study participation.
Lab values
- Clinically significant abnormal laboratory values available vital signs, ECG, or laboratory testing at the screening assessment that, which in the opinion of the investigator, could interfere with the objectives of the study or safety of the participant. -Current diagnosis of asthma.
Other
- The participant has an altered mental status at the time of informed consent.
- Female participants who are pregnant.
Who the study is looking for
- Capable of giving signed ICF
- Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 acceptability criteria.
- Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center.
- Participants will be allowed to enroll into other non-intervention studies while taking part in this study.
Age in the registry: 30 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| - Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
| - Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
| - Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
| - Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
| - Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
| - Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| - Coordinator of this site? Confirm its status | Shenyang | China | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
| - Coordinator of this site? Confirm its status | Xuzhou | China | Recruiting |
| - Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.